Tuberculosis
and parasitic diseases, such as giardiasis, amebiasis,
leishmaniasis, and trypanosomiasis, all urgently require improved
treatment options. Recently, it has been shown that antitubercular
bicyclic nitroimidazoles such as pretomanid and delamanid have potential
as repurposed therapeutics for the treatment of visceral leishmaniasis.
Here, we show that pretomanid also possesses potent activity against Giardia lamblia and Entamoeba histolytica, thus expanding the therapeutic potential of nitroimidazooxazines.
Synthetic analogues with a novel nitroimidazopyrazin-one/-e bicyclic
nitroimidazole chemotype were designed and synthesized, and structure–activity
relationships were generated. Selected derivatives had potent antiparasitic
and antitubercular activity while maintaining drug-like properties
such as low cytotoxicity, good metabolic stability in liver microsomes
and high apparent permeability across Caco-2 cells. The kinetic solubility
of the new bicyclic derivatives varied and was found to be a key parameter
for future optimization. Taken together, these results suggest that
promising subclasses of bicyclic nitroimidazoles containing different
core architectures have potential for further development.